Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE

Monte Rosa Therapeutics stock price today

$4.4
-2.65
-37.68%
Financial Health
0
1
2
3
4
5
6
7
8
9

Monte Rosa Therapeutics stock price monthly change

+63.43%
month

Monte Rosa Therapeutics stock price quarterly change

+63.43%
quarter

Monte Rosa Therapeutics stock price yearly change

+22.57%
year

Monte Rosa Therapeutics key metrics

Market Cap
427.59M
Enterprise value
389.59M
P/E
-3.65
EV/Sales
N/A
EV/EBITDA
-3.85
Price/Sales
N/A
Price/Book
1.46
PEG ratio
-0.16
EPS
-2.51
Revenue
N/A
EBITDA
-138.79M
Income
-135.28M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Monte Rosa Therapeutics stock price history

Monte Rosa Therapeutics stock forecast

Monte Rosa Therapeutics financial statements

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Profit margin
Jun 2023 0 -35.17M
Sep 2023 0 -34.88M
Dec 2023 8.75M -33.25M -379.94%
Mar 2024 1.06M -31.96M -3004.51%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Analyst Estimates
Mar 2024 1.06M -31.96M -3004.51%
Sep 2025 2.2M -34.34M -1561.24%
Oct 2025 2.72M -29.12M -1070.23%
Dec 2025 6.14M -28.23M -459.26%
  • Analysts Price target

  • Financials & Ratios estimates

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Earnings per share (EPS)
2023-11-09 -0.75 -0.7
2024-03-14 -0.57 -0.58
2024-05-09 -0.56 -0.53
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Debt to assets
Jun 2023 278616000 64.96M 23.32%
Sep 2023 252103000 67.57M 26.81%
Dec 2023 303755000 124.50M 40.99%
Mar 2024 266745999 114.22M 42.82%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Cash Flow
Jun 2023 -25.32M 18.55M 1.2M
Sep 2023 -24.70M 35.62M 1.10M
Dec 2023 29.63M 14.29M 25.17M
Mar 2024 -38.16M 9.85M 246K

Monte Rosa Therapeutics alternative data

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Employee count
Aug 2023 133
Sep 2023 133
Oct 2023 133
Nov 2023 133
Dec 2023 133
Jan 2024 133
Feb 2024 133
Mar 2024 133
Apr 2024 133
May 2024 133
Jun 2024 130
Jul 2024 130

Monte Rosa Therapeutics other data

30.06% -58.37%
of GLUE is owned by hedge funds
14.19M -27.12M
shares is hold by hedge funds

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Insider trades (number of shares)
Period Buy Sel
Jun 2024 0 1207
Jul 2024 0 1610
Sep 2024 0 1699779
Oct 2024 0 157895
Transaction Date Insider Security Shares Price per share Total value Source
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 52,305 $9.08 $475,034
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 15,600 $9.41 $146,796
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 89,990 $9.66 $869,213
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 1,132,566 $6.53 $7,395,656
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 9,269 $6.16 $57,097
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 16,047 $6 $96,314
Sale
VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner
Common Stock 541,897 $6 $3,251,382
Sale
DUNN EDMUND officer: Principal Accounting O..
Common Stock 1,610 $3.83 $6,166
Sale
DUNN EDMUND officer: Principal Accounting O..
Common Stock 1,207 $4.04 $4,876
Purchase
WALKER PAUL EDWARD 10 percent owner Common Stock 1,050,000 $19 $19,950,000
Insider Compensation
Dr. Markus Warmuth M.D. (1971) Pres, Chief Executive Officer & Director $899,170
Mr. Ajim A. Tamboli C.F.A. (1977) Chief Financial Officer
$404,690
Monday, 23 December 2024
zacks.com
Friday, 13 December 2024
globenewswire.com
Wednesday, 11 December 2024
globenewswire.com
globenewswire.com
Thursday, 5 December 2024
globenewswire.com
Monday, 2 December 2024
zacks.com
Tuesday, 26 November 2024
globenewswire.com
Friday, 15 November 2024
zacks.com
Thursday, 7 November 2024
zacks.com
Wednesday, 6 November 2024
zacks.com
Wednesday, 30 October 2024
zacks.com
Monday, 28 October 2024
investopedia.com
investors.com
globenewswire.com
Monday, 19 August 2024
globenewswire.com
Thursday, 8 August 2024
zacks.com
globenewswire.com
Monday, 8 July 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
Friday, 14 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Thursday, 2 May 2024
globenewswire.com
Wednesday, 10 April 2024
Zacks Investment Research
Thursday, 4 April 2024
Zacks Investment Research
Friday, 22 March 2024
Zacks Investment Research
  • What's the price of Monte Rosa Therapeutics stock today?

    One share of Monte Rosa Therapeutics stock can currently be purchased for approximately $4.4.

  • When is Monte Rosa Therapeutics's next earnings date?

    Unfortunately, Monte Rosa Therapeutics's (GLUE) next earnings date is currently unknown.

  • Does Monte Rosa Therapeutics pay dividends?

    No, Monte Rosa Therapeutics does not pay dividends.

  • How much money does Monte Rosa Therapeutics make?

    Monte Rosa Therapeutics has a market capitalization of 427.59M. Monte Rosa Therapeutics made a loss 135.35M US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.

  • What is Monte Rosa Therapeutics's stock symbol?

    Monte Rosa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GLUE".

  • What is Monte Rosa Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Monte Rosa Therapeutics?

    Shares of Monte Rosa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Monte Rosa Therapeutics's key executives?

    Monte Rosa Therapeutics's management team includes the following people:

    • Dr. Markus Warmuth M.D. Pres, Chief Executive Officer & Director(age: 54, pay: $899,170)
    • Mr. Ajim A. Tamboli C.F.A. Chief Financial Officer(age: 48, pay: $404,690)
  • How many employees does Monte Rosa Therapeutics have?

    As Jul 2024, Monte Rosa Therapeutics employs 130 workers, which is 2% less then previous quarter.

  • When Monte Rosa Therapeutics went public?

    Monte Rosa Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 24 Jun 2021.

  • What is Monte Rosa Therapeutics's official website?

    The official website for Monte Rosa Therapeutics is monterosatx.com.

  • Where are Monte Rosa Therapeutics's headquarters?

    Monte Rosa Therapeutics is headquartered at 645 Summer Street, Boston, MA.

  • How can i contact Monte Rosa Therapeutics?

    Monte Rosa Therapeutics's mailing address is 645 Summer Street, Boston, MA and company can be reached via phone at +61 79492643.

Monte Rosa Therapeutics company profile:

Monte Rosa Therapeutics, Inc.

monterosatx.com
Exchange:

NASDAQ

Full time employees:

133

Industry:

Biotechnology

Sector:

Healthcare

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

645 Summer Street
Boston, MA 02210

CIK: 0001826457
ISIN: US61225M1027
CUSIP: 61225M102